Lamivudine;拉米夫定

Genotyping Anti-Hepatitis B Virus Drug Resistance

, such as lamivudine and adefovir (1 ). Currently, the only therapies approved in the United States for treatment of chronic HBV infection are IFN-α and lamivudine. However, a number of nucleoside and nucleotide analogs are in development, and it is likely

乙型肝炎病毒YMDD基因突变检测芯片试剂盒

　　乙肝病毒YMDD基因突变检测芯片试剂盒是专门为服用或准备服用拉米夫定（贺普丁）的慢性乙肝患者设计生产的。 　　该产品可以准确检测出拉米夫定（贺普丁）耐药病毒株的存在，为临床医生及时发现HBV病毒变异，调整治疗方案提供有效帮助，避免拉米夫定因耐药性无效用药及由此带来的副作用、减轻患者不必要的经济负担，具有重大的商业与社会价值。 　　该产品利用“基因芯片”这一高新基因分析技术，合理设计、优化组合，准确判断HBV野生株、突变株及其共生状态和相对优势株，同一

Hepatitis B Virus Transgenic Severe Combined Immunodeficient Mouse Model of Acute and Chronic Liver Disease

(4 ). While the survival rate for HCC is 5 ). Interferon produces a sustained virus response in only about 20% of patients following the end of therapy (5 ,6 ). Lamivudine is highly effective against both virus and liver disease, although a high rate of virus resistance